Tarsier Pharma receives FDA agreement under Special Protocol Assessment for Tarsier-04 Phase 3 Trial

Alan Palestine, MD, director Center for Ocular Inflammation at the University of Colorado Department of Ophthalmology expresses optimism that the field is closer than ever to controlling inflammation without increasing the risk of glaucoma.